Plavix
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Plavix (clopidogrel; Sanofi/Bristol-Myers Squibb) is an antiplatelet agent that inhibits blood clot formation. It works by irreversibly binding to the blood platelet’s adenosine diphosphate (ADP) P2Y12 receptor, preventing ADP-mediated activation of the glycoprotein IIb/IIIa complex. By preventing the activation of this complex, Plavix prevents platelet aggregation from occurring, and prevents the formation of blood clots.
CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Plavix : Stroke
18 Plavix : Acute coronary syndrome (ACS)
LIST OF FIGURES
11 Figure 1: Plavix for ischemic stroke – SWOT analysis
12 Figure 2: Datamonitor Healthcare’s drug assessment summary of Plavix for ischemic stroke
13 Figure 3: Datamonitor Healthcare’s drug assessment summary of Plavix for ischemic stroke
15 Figure 4: Plavix sales for ischemic stroke across the US, Japan, and five major EU markets, by country, 2016–25
22 Figure 5: Plavix for acute coronary syndrome – SWOT analysis
23 Figure 6: Datamonitor Healthcare’s drug assessment summary for Plavix in acute coronary syndrome
24 Figure 7: Datamonitor Healthcare’s drug assessment summary for Plavix in acute coronary syndrome
LIST OF TABLES
6 Table 1: Plavix drug profile
8 Table 2: Plavix pivotal trial data in ischemic stroke
10 Table 3: Plavix ongoing late-phase clinical trials in ischemic stroke
16 Table 4: Plavix sales for ischemic stroke across the US, Japan, and five major EU markets, by country ($m), 2016–25
19 Table 5: Plavix drug profile
21 Table 6: Plavix pivotal trial data in acute coronary syndrome
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Aspirin 
Sign up to the